An international consortium identifies and validates cellular role of priority Parkinson’s disease drug target, LRRK2 kinase, in a new study, illuminating a novel route for therapeutic development and intervention testing for Parkinson’s, the second most common neurodegenerative disease after Alzheimer’s.